Calidi presents RTNova data supporting systemic targeting of metastatic lung cancer at IOVC and SITC

Calidi Biotherapeutics, Inc.

Data presented at IOVC and SITC shows RTNova enveloped virotherapy can target multiple metastatic tumor sites.
RTNova uses tumor-selective vaccinia virus engineered to produce high levels of EEVs to avoid immune clearance.
In an advanced lung metastasis model, RTNova demonstrated robust therapeutic potential as monotherapy and viral vector.
The platform can induce expression of engineered payloads in tumor cells, enabling future delivery of therapeutic genes.
Calidi plans to advance RTNova as a multi-modal systemic antitumor virotherapy and seek pharma collaborations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.